Logo image of PRLD

PRELUDE THERAPEUTICS INC (PRLD) Stock Price, Quote, News and Overview

NASDAQ:PRLD - Nasdaq - US74065P1012 - Common Stock - Currency: USD

1.09  +0.08 (+7.92%)

After market: 0.9 -0.19 (-17.43%)

PRLD Quote, Performance and Key Statistics

PRELUDE THERAPEUTICS INC

NASDAQ:PRLD (2/10/2025, 8:18:45 PM)

After market: 0.9 -0.19 (-17.43%)

1.09

+0.08 (+7.92%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High6.8
52 Week Low0.8
Market Cap59.99M
Shares55.04M
Float27.32M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)02-13 2025-02-13/amc
IPO09-25 2020-09-25


PRLD short term performance overview.The bars show the price performance of PRLD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

PRLD long term performance overview.The bars show the price performance of PRLD in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PRLD is 1.09 USD. In the past month the price increased by 2.83%. In the past year, price decreased by -76.46%.

PRELUDE THERAPEUTICS INC / PRLD Daily stock chart

PRLD Latest News and Analysis

News Image
13 hours ago - Chartmill

Stay updated with the stocks that are on the move in today's after-hours session.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

News Image
2 months ago - Prelude Therapeutics, Incorporated

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy •...

News Image
3 months ago - Prelude Therapeutics, Incorporated

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology...

PRLD Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.81 336.36B
AMGN AMGEN INC 14.87 158.46B
VRTX VERTEX PHARMACEUTICALS INC 1620.59 121.03B
GILD GILEAD SCIENCES INC 21.55 118.99B
REGN REGENERON PHARMACEUTICALS 15.13 75.86B
ARGX ARGENX SE - ADR N/A 38.66B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.35B
BNTX BIONTECH SE-ADR N/A 27.63B
ONC BEIGENE LTD-ADR N/A 23.41B
NTRA NATERA INC N/A 22.73B
BIIB BIOGEN INC 8.73 20.77B
UTHR UNITED THERAPEUTICS CORP 15.18 15.43B

About PRLD

Company Profile

PRLD logo image Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 128 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.

Company Info

PRELUDE THERAPEUTICS INC

175 Innovation Boulevard

Wilmington DELAWARE 19803 US

CEO: Krishna Vaddi

Employees: 128

Company Website: https://preludetx.com/

Investor Relations: https://investors.preludetx.com/

Phone: 13024671280

PRLD FAQ

What is the stock price of PRLD?

The current stock price of PRLD is 1.09 USD.


What is the symbol for PRELUDE THERAPEUTICS INC stock?

The exchange symbol of PRELUDE THERAPEUTICS INC is PRLD and it is listed on the Nasdaq exchange.


On which exchange is PRLD stock listed?

PRLD stock is listed on the Nasdaq exchange.


Is PRLD a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PRLD, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PRLD.


Does PRLD stock pay dividends?

PRLD does not pay a dividend.


When does PRLD stock report earnings?

PRLD will report earnings on 2025-02-13, after the market close.


What is the Price/Earnings (PE) ratio of PRLD?

PRLD does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.77).


What is the Short Interest ratio of PRLD stock?

The outstanding short interest for PRLD is 11.41% of its float.


PRLD Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to PRLD. When comparing the yearly performance of all stocks, PRLD is a bad performer in the overall market: 93.09% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PRLD Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PRLD. While PRLD has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PRLD Financial Highlights

Over the last trailing twelve months PRLD reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS increased by 18.43% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -66.69%
ROE -84.07%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%4.44%
Sales Q2Q%N/A
EPS 1Y (TTM)18.43%
Revenue 1Y (TTM)N/A

PRLD Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 76% to PRLD. The Buy consensus is the average rating of analysts ratings from 11 analysts.


Ownership
Inst Owners54.82%
Ins Owners8.97%
Short Float %11.41%
Short Ratio6.53
Analysts
Analysts76.36
Price Target5.1 (367.89%)
EPS Next Y10.81%
Revenue Next YearN/A